Current Liabilities decreased faster than Xilio Therapeutics Inc 's Cash & cash equivalent, this led to improvement in Xilio Therapeutics Inc 's Quick Ratio to 3.47, Quick Ratio remained below Xilio Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 227 other companies have achieved higher Quick Ratio than Xilio Therapeutics Inc in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 1005, from total ranking in the second quarter 2026 at 1531.

Explain Quick Ratio?
How much Cash & cash equivalents XLO�s has?
What are XLO�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/XLO/financial-strength

https://api.csimarket.com/api/v1/companies/XLO/fundamentals

https://api.csimarket.com/api/v1/companies/XLO/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

XLO Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	-36.01 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	17.75 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	3.47	Subscribe	Subscribe	Subscribe	Subscribe
XLO's Total Ranking	# 1005	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-22.49 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-10.19 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 228
Healthcare Sector	# 379
Overall Market	# 1024

Quick Ratio Statistics
High	Average	Low
16.54	4.9	0.89
(Dec 31 2021)		(Dec 31 2020)

Financial Statements
Xilio Therapeutics Inc 's Current Liabilities	$ 35 Millions	Visit XLO's Balance sheet
Xilio Therapeutics Inc 's Cash & cash equivalent	$ 122 Millions	Visit XLO's Balance sheet
Source of XLO's Sales		Visit XLO's Sales by Geography

Cumulative Xilio Therapeutics Inc 's Quick Ratio

XLO's Quick Ratio for the trailling 12 Months

XLO Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-10.86 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	47.72 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	3.08	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3741	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	-10.07 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	3.49 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to XLO Financial Strength Comparisons >> Go to Compare XLO Quick Ratio to its Competitors

On the trailing twelve months basis XLO Cash & cash equivalent increased by 17.75 % in Q3 2026 year on year, while Current Liabilities faded to $35 millions, this led to increase in in Xilio Therapeutics Inc 's Quick Ratio to 3.08, Quick Ratio remained below XLO average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 428 other companies have achieved higher Quick Ratio than Xilio Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2908 to 3741.

Explain Quick Ratio?
How much Cash & cash equivalents XLO�s has?
What are XLO�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 429
Healthcare Sector	# 873
Within the Market	# 3741

trailing twelve months Quick Ratio Statistics
High	Average	Low
11.4	4.63	1.66
(Jun 30 2022)		(Dec 31 2024)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Aprea Therapeutics Inc	9.52	$ 37.846 Millions	$ 3.975 Millions
Rezolute Inc	9.51	$ 89.999 Millions	$ 9.463 Millions
Opus Genetics Inc	9.05	$ 88.974 Millions	$ 9.832 Millions
Ibio inc	8.94	$ 76.654 Millions	$ 8.574 Millions
Ideaya Biosciences Inc	8.70	$ 838.541 Millions	$ 96.405 Millions
First Tracks Biotherapeutics Inc	8.60	$ 155.627 Millions	$ 18.090 Millions
Pepgen Inc	8.48	$ 104.805 Millions	$ 12.361 Millions
Ocular Therapeutix Inc	8.42	$ 530.612 Millions	$ 63.017 Millions
Arvinas Inc	7.98	$ 558.400 Millions	$ 70.000 Millions
Wave Life Sciences Ltd	7.87	$ 431.012 Millions	$ 54.760 Millions
Savara Inc	7.80	$ 129.649 Millions	$ 16.630 Millions
Rigel Pharmaceuticals Inc	7.79	$ 224.456 Millions	$ 28.806 Millions
Cytomx Therapeutics Inc	7.64	$ 347.980 Millions	$ 45.532 Millions
Atea Pharmaceuticals Inc	7.64	$ 191.199 Millions	$ 25.025 Millions
Braveheart Bio, Inc.	7.27	$ 121.291 Millions	$ 16.673 Millions
Viking Therapeutics Inc	7.17	$ 959.813 Millions	$ 133.897 Millions
Scynexis Inc	7.09	$ 47.165 Millions	$ 6.652 Millions
Lb Pharmaceuticals Inc	7.03	$ 215.075 Millions	$ 30.573 Millions
Zentalis Pharmaceuticals Inc	7.03	$ 228.893 Millions	$ 32.539 Millions
Quoin Pharmaceuticals Ltd	6.95	$ 33.184 Millions	$ 4.776 Millions
Vera Therapeutics Inc	6.89	$ 384.042 Millions	$ 55.775 Millions
Nuvation Bio Inc	6.73	$ 663.370 Millions	$ 98.559 Millions
Coya Therapeutics Inc	6.64	$ 35.802 Millions	$ 5.395 Millions
Capricor Therapeutics inc	6.61	$ 197.581 Millions	$ 29.895 Millions
Arcturus Therapeutics Holdings Inc	6.52	$ 184.817 Millions	$ 28.345 Millions
Moonlake Immunotherapeutics	6.50	$ 379.704 Millions	$ 58.430 Millions
Camp4 Therapeutics Corporation	6.27	$ 124.522 Millions	$ 19.865 Millions
Context Therapeutics Inc	6.26	$ 34.411 Millions	$ 5.501 Millions
Bridgebio Oncology Therapeutics Inc	6.18	$ 315.331 Millions	$ 51.026 Millions
Cartesian Therapeutics Inc	6.12	$ 122.975 Millions	$ 20.088 Millions

Date modified: 2026-11-11T14:07:28+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.